Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04214093 · ClinicalTrials.gov registry record · Phase 1
A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT04214093 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 9 participants.
The verdict
NCT04214093, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a first-time-in-human (FTIH), Phase 1 study to determine the safety, tolerability, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of AZD0466 in patients with solid tumors, lymphoma and multiple myeloma at low risk for tumor lysis syndrome (TLS), as well as in patients at intermediate risk or high risk of TLS with hematologic malignancies for whom no standard therapy exists. Once an MTD/RP2D has been determined in the dose escalation portion, further disease-specific expansions (solid tumor and hematologic) will be undertaken. Combinations of AZD0466 with other standard of care treatments may be evaluated in the future.
Interventions
- DRUG AZD0466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2021-06-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04214093
The ClinicalTrials.gov registry entry for NCT04214093 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD0466 is the first listed.
NCT04214093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04214093 about?
NCT04214093 is a clinical study titled "A Study of AZD0466 in Patients With Advanced Hematologic or Solid Tumors". This is a first-time-in-human (FTIH), Phase 1 study to determine the safety, tolerability, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and pharmacokinetics (PK) of AZD0466 in patients with solid tumors, lymphoma and multiple myeloma at low risk for tumor lysis syndrome (TLS), as w...
What is the current status of trial NCT04214093?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-12-16. Estimated completion is 2021-06-18.
What interventions are being tested in trial NCT04214093?
The interventions under investigation include: AZD0466 (DRUG).
Who is sponsoring clinical trial NCT04214093?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.